These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1109 related articles for article (PubMed ID: 9149200)
21. High plasma levels of atrial natriuretic peptide in preascitic cirrhosis: indirect evidence of reduced natriuretic effectiveness of the peptide. Trevisani F; Colantoni A; Sica G; Gasbarrini A; D'Intino PE; De Notariis S; De Jaso R; Barbieri A; Morselli A; Gasbarrini G Hepatology; 1995 Jul; 22(1):132-7. PubMed ID: 7601404 [TBL] [Abstract][Full Text] [Related]
22. Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failure. Rademaker MT; Charles CJ; Nicholls MG; Richards AM Circ Heart Fail; 2008 Jul; 1(2):134-42. PubMed ID: 19808282 [TBL] [Abstract][Full Text] [Related]
23. [Acute changes in the hemodynamic profile and circulating levels of atrial natriuretic peptide induced by dobutamine in severe heart failure]. La Vecchia L; Bottero M; Centofante P; Bedogni F; Ometto R; Cera A; Fortunato A G Ital Cardiol; 1996 Aug; 26(8):863-74. PubMed ID: 9005168 [TBL] [Abstract][Full Text] [Related]
24. Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. Sansoè G; Silvano S; Mengozzi G; Smedile A; Todros L; Baronio M; Bonardi L; Rizzetto M Am J Gastroenterol; 2002 Sep; 97(9):2383-90. PubMed ID: 12358261 [TBL] [Abstract][Full Text] [Related]
25. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. Davis ME; Pemberton CJ; Yandle TG; Fisher SF; Lainchbury JG; Frampton CM; Rademaker MT; Richards AM J Am Coll Cardiol; 2007 Jan; 49(4):461-71. PubMed ID: 17258092 [TBL] [Abstract][Full Text] [Related]
26. Effects of human atrial natriuretic peptide on cardiac function and hemodynamics in patients with high plasma BNP levels. Nakajima K; Onishi K; Dohi K; Tanabe M; Kurita T; Yamanaka T; Ito M; Isaka N; Nobori T; Nakano T Int J Cardiol; 2005 Oct; 104(3):332-7. PubMed ID: 16186065 [TBL] [Abstract][Full Text] [Related]
27. Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. Moe GW; Canepa-Anson R; Armstrong PW J Cardiovasc Pharmacol; 1992 May; 19(5):691-700. PubMed ID: 1381766 [TBL] [Abstract][Full Text] [Related]
28. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome. Plum J; Mirzaian Y; Grabensee B Nephrol Dial Transplant; 1996 Jun; 11(6):1034-42. PubMed ID: 8671965 [TBL] [Abstract][Full Text] [Related]
29. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. Richards AM; Crozier IG; Espiner EA; Ikram H; Yandle TG; Kosoglou T; Rallings M; Frampton C J Cardiovasc Pharmacol; 1992; 20(5):735-41. PubMed ID: 1280735 [TBL] [Abstract][Full Text] [Related]
30. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Laffi G; Pinzani M; Meacci E; La Villa G; Renzi D; Baldi E; Cominelli F; Marra F; Gentilini P Gastroenterology; 1989 Jan; 96(1):167-77. PubMed ID: 2535828 [TBL] [Abstract][Full Text] [Related]
31. Renal actions of theophylline and atrial natriuretic peptide in humans: a comparison by means of clearance studies. Beutler JJ; Koomans HA; Bijlsma JA; Dorhout Mees EJ J Pharmacol Exp Ther; 1990 Dec; 255(3):1314-9. PubMed ID: 2148189 [TBL] [Abstract][Full Text] [Related]
32. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study. Hadengue A; Moreau R; Bacq Y; Gaudin C; Braillon A; Lebrec D Hepatology; 1991 Jan; 13(1):111-6. PubMed ID: 1671029 [TBL] [Abstract][Full Text] [Related]
33. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Wong F; Pantea L; Sniderman K Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086 [TBL] [Abstract][Full Text] [Related]
34. Human atrial natriuretic peptide: plasma levels, hemodynamic, hormonal, and renal effects in patients with severe congestive heart failure. Riegger GA; Kromer EP; Kochsiek K J Cardiovasc Pharmacol; 1986; 8(6):1107-12. PubMed ID: 2434734 [TBL] [Abstract][Full Text] [Related]
35. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Wong F; Liu P; Lilly L; Bomzon A; Blendis L Clin Sci (Lond); 1999 Sep; 97(3):259-67. PubMed ID: 10464050 [TBL] [Abstract][Full Text] [Related]
36. [Renal tubular function in cirrhotic patients with ascites: special reference to lithium clearance following the human atrial natriuretic peptide administration]. Ando M Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):791-801. PubMed ID: 1837568 [TBL] [Abstract][Full Text] [Related]
37. Radioimmunoassay of atrial natriuretic peptide in human plasma: application to studies of volume and blood pressure homeostasis. Horký K; Srámková J; Tesar V; Lachmanová J; Widimský J Physiol Bohemoslov; 1988; 37(4):299-305. PubMed ID: 2973615 [TBL] [Abstract][Full Text] [Related]
38. Low-dose enoximone therapy in pre-transplant patients: hemodynamic, echocardiographic, and neurohumoral findings. Park JW; Heinzler R; Wirtz JH; Fieten-Rumswinkel M; Braun P; May E; Hetzer R; Heinrich KW Z Kardiol; 1994; 83 Suppl 2():49-53. PubMed ID: 8091824 [TBL] [Abstract][Full Text] [Related]
39. [Mutual interaction of the renin-angiotensin system and the atrial natriuretic factor in the renal response to acute volume loading]. Horký K; Tesar V; Gregorová I; Srámková J; Dvoráková J Vnitr Lek; 1990 Jul; 36(7):625-32. PubMed ID: 2147304 [TBL] [Abstract][Full Text] [Related]